ClinicalTrials.gg
Active, not recruitingNCT06736418Updated Apr 24, 2026

Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

A Phase 1 interventional study of 225Ac-ABD147 in Small-Cell Lung Cancer (SCLC) and Large Cell Neuroendocrine Carcinoma of the Lung, sponsored by Abdera Therapeutics Inc.. Active, not recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Abdera Therapeutics Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 630 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Enrollment
454th of 551
17 · median 55
Started
2025
with 39 others
Phase 1
183 of 630
24 open now
Primary completion
2026-08
later than 37 of 181 live
Registered
561st of 630
by date

Among the 630 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 454th largest by enrollment of the 551 interventional ones that give a count, is one of 40 that started in 2025, is one of 183 in phase 1, reaches primary completion later than 37 of the 181 other live ones, and was the 561st registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

111 of the 630 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 630 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of the lung following platinum-based chemotherapy.

An initial group of patients will also be given an experimental imaging agent called 111In-ABD147 to help understand where ABD147 goes in the body.

The goal of Phase 1b is to gather additional safety and efficacy data on 225Ac-ABD147 to determine the best dose and to understand how those doses affect the same types of patients' cancers explored enrolled in Phase 1a.

Read the detailed description

This is an open-label, Phase 1a/b, first-in-human study to assess the safety profile, tolerability, biodistribution, pharmacokinetics (PK), and preliminary antitumor activity of 225Ac-ABD147 in patients with confirmed locally advanced or metastatic small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of the lung. All patients must have previously received platinum-based chemotherapy.

Phase 1a will determine the safety, tolerability, dosimetry, PK, and the dose of 225Ac-ABD147 for expansion in the Phase 1b portion.

In addition to receiving treatment, a subset of patients in Phase 1a will undergo either 111In-ABD147-based or 225Ac-ABD147 dosimetry assessments to confirm tumor specificity, identify biodistribution, and to provide insight into dose absorption into tumor and normal tissues.

Phase 1b will evaluate the safety and preliminary efficacy of 225Ac-ABD147 as based on the Phase 1a dose level for expansion by the Safety Review Committee to determine the recommended Phase 2 dose (RP2D).

03

Conditions studied

  • Small-Cell Lung Cancer (SCLC)
  • Large Cell Neuroendocrine Carcinoma of the Lung

Keywords

  • Actinium
  • Ac-225
  • 225Ac-ABD147
  • Indium
  • In-111
  • 111In-ABD147
  • ABD147
  • Abdera Therapeutics
  • Abdera
  • ROVEr
  • Ac
  • In
  • ABD-147
  • Small Cell Lung Cancer
  • Small-Cell Lung Cancer
  • SCLC
  • Large Cell Neuroendocrine Carcinoma
  • Large-Cell Neuroendocrine Carcinoma
  • LCNEC
  • Lung Cancer
  • Delta-Like Ligand 3
  • Delta Like Ligand 3
  • Delta-Like Protein 3
  • Delta Like Protein 3
  • Delta-Like Canonical Notch Ligand 3
  • Delta Like Canonical Notch Ligand 3
  • Delta3
  • DLL3
  • Precision Radiopharmaceutical
  • Radiopharmaceutical
  • Radiotherapy
  • Radioligand
  • Linker-Chelator
  • Linker Chelator
  • VHH-Fc
  • HH-FcRN
  • Biologic
  • Antibody
  • Antibodies
  • Nuclide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Has confirmed, locally advanced or SCLC or LCNEC of the lung.
  • Has received platinum-based chemotherapy.
  • Mentally competent and able to understand and sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved Form (ICF) prior to any study specific evaluation.
  • Age ≥18 years old at the time the ICF is signed.
  • (ECOG) performance status (PS) of 0 to 1.
  • Expected of >12 weeks per the Investigator.
  • Has disease that is measurable by v1.1.
  • Patients with known are eligible provided they are considered by the Investigator to be neurologically stable and meet the following criteria: a. Radiotherapy or surgery for brain metastases was completed at least 2 weeks prior to Cycle 1 Day 1 (C1D1); b. Symptoms are stable and /antiepileptic doses remain unchanged for a minimum of 2 weeks prior to C1D1.
  • At least 4 weeks from prior major surgery (other than for brain metastases), or at least 7 days from prior non-study-related minor surgery prior to C1D1. In all cases, the patient must be sufficiently recovered and stable before the study treatment administration.
  • Willing to provide for central analysis; if unavailable, a pre-study treatment biopsy may be collected and provided.
  • Female and male patients of agree to use at least 2 highly effective forms of (1 at least must be barrier method) or agree to completely remain abstinent for duration of study and for 6 months after the last administration of study drug for both female patients and male patients.
  • Patients agree to not make semen/egg donations during treatment, within 2 weeks following the last dose of 111In-ABD147, and for 6 months following the last dose of 225Ac-ABD147.

Key Exclusion Criteria:

  • Was previously treated with 225Ac-ABD147.
  • Has a history of steroid dependent hepatitis caused by treatment with a .
  • Is actively enrolled in another clinical study unless it is an observational (noninterventional) clinical study or the follow-up component of an interventional study.
  • Use of an anticancer therapy, radiotherapy (external beam radiotherapy [EBRT], brachytherapy, inoperative radiation therapy, radiopharmaceuticals), or immunotherapy within 3 weeks prior to C1D1. Prior treatment with DLL3-targeting agent is acceptable with appropriate .
  • Has a medical history of myocardial infarction or unstable angina within 6 months before C1D1.
  • Has cardiac disease not controlled by medical therapy (eg, congestive cardiac failure, arrhythmia, coronary heart disease).
  • Has evidence of active infection requiring intravenous (IV) antibiotics during Screening requiring therapy within 7 days prior to C1D1.
  • Has active uncontrolled bleeding or a bleeding diathesis within 28 days prior to C1D1.
  • Has serious or non-healing wound, fistula, skin ulcer, or non-healing bone fracture within 7 days prior to C1D1.
  • Has received any thoracic radiotherapy within 8 weeks prior to C1D1.
  • Has a history of idiopathic pulmonary fibrosis, organizing pneumonia (eg, bronchiolitis obliterans), drug-induced pneumonitis (requiring steroids or agents), or idiopathic pneumonitis, or evidence of active pneumonitis on the Screening chest computed tomography (CT) scan. Note: History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  • Has known to Ac-225; for patients participating in the 111In-ABD147 dosimetry substudy, also has known hypersensitivity to In-111.
  • Has known hypersensitivity to Chinese hamster ovary cell products.
  • Has a history of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.
  • Has infection; patients who are taking an effective antiviral therapy with undetectable viral load prior to C1D1 are eligible.
  • Has chronic virus (HBV) infection. Patients who are taking an effective suppressive therapy and have an undetectable HBV viral load are eligible.
  • Has a history of virus (HCV) infection, unless treated and cured; patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible.
  • Has carcinomatous meningitis.
  • Has active symptomatic cord compression.
  • Has active symptomatic superior vena cava syndrome.
  • Has another primary that has not been treated with curative intent (discuss with Medical Monitor), except for non-metastatic cutaneous basal cell or squamous cell carcinoma, or non-muscle invasive bladder cancer.
  • Is unwilling or unable to follow protocol requirements.
  • Has any condition that, in the opinion of the Investigator, would interfere with evaluation of the product or interpretation of the patient's safety or study results.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Phase 1a Dose Escalation Group

    225Ac-ABD147 administered in escalating dose cohorts

    Drug: 225Ac-ABD147

  • Experimental
    Phase 1b Dose Expansion Group

    Expansion Dose Level selected from Phase 1a Dose Escalation

    Drug: 225Ac-ABD147

Interventions

  • Drug225Ac-ABD147

    A delta-like ligand 3 (DLL3)-targeting antibody fragment conjugated with a linker-chelator that effectively coordinates Ac-225

06

What researchers measure

Primary outcomes

  1. Ph 1a: Safety of 225Ac-ABD147 - Number and Grade of Adverse Events

    Incidence of adverse events and serious adverse events graded according to NCI-CTCAE v5.0; Clinically significant changes from baseline for laboratory values, ECGs, and vital signs will be evaluated as adverse events.

    Time frame: 12 months

  2. Ph 1a: Tolerability of 225Ac-ABD147 - Number of Dose Limiting Toxicities

    Incidence and nature of dose limiting toxicities.

    Time frame: 12 months

  3. Ph 1b: Safety of 225Ac-ABD147 to Determine the RP2D for Further Development - Number and Grade of Adverse Events

    Incidence of adverse events and serious adverse events graded according to NCI-CTCAE v5.0; Clinically significant changes from baseline for laboratory values, ECGs, and vital signs will be evaluated as adverse events.

    Time frame: 12 months

  4. Ph 1b: Preliminary Efficacy of 225Ac-ABD147 - Overall Response Rate (ORR)

    ORR of confirmed complete response (CR) and partial response (PR) per investigator assessment using RECIST v1.1.

    Time frame: 12 months

  5. Ph 1b: Preliminary Efficacy of 225Ac-ABD147 - Disease Control Rate (DCR)

    DCR per investigator assessment using RECIST v1.1.

    Time frame: 12 months

  6. Ph 1b: Preliminary Efficacy of 225Ac-ABD147 - Duration of Response (DOR)

    DOR of confirmed CR and PR per investigator assessment using RECIST v1.1.

    Time frame: 12 months

  7. Ph 1b: Preliminary Efficacy of 225Ac-ABD147 - Duration of Progression Free Survival (PFS)

    PFS per investigator assessment using RECIST v1.1.

    Time frame: 12 months

  8. Ph 1b: Preliminary Efficacy of 225Ac-ABD147 - Overall Survival (OS)

    OS.

    Time frame: 12 months

  9. Ph 1b: Preliminary Efficacy of 225Ac-ABD147 - PFS Rate

    6 monthly PFS rate per investigator assessment using RECIST v1.1.

    Time frame: 12 months

  10. Ph 1b: Preliminary Efficacy of 225Ac-ABD147 - OS Rate

    6 monthly OS rate.

    Time frame: 12 months

  11. Ph 1b: Biodistribution and Absorbed Dose - Measurement of Activity

    Whole blood radioactivity with whole blood gamma counting.

    Time frame: 6 months

  12. Ph 1b: Immunogenicity of 225Ac-ABD147 - Measurement of Anti-drug Antibodies

    Anti-drug antibody to ABD147.

    Time frame: 6 months

Secondary outcomes

  1. Ph 1a: Determination of 225Ac-ABD147 Dose for Expansion (Phase 1b)

    The dose for expansion (Phase 1b) will be determined by integrating the totality of data obtained in Phase 1a.

    Time frame: 12 months

  2. Ph 1a: Safety and Tolerability of Multiples Doses of 225Ac-ABD147 - Number and Grade of Adverse Events

    Incidence of adverse events and serious adverse events graded according to NCI-CTCAE v5.0; Clinically significant changes from baseline for laboratory values, ECGs, and vital signs will be evaluated as adverse events.

    Time frame: 12 months

  3. Ph 1a: PK Profile of 225Ac-ABD147 - Peak Plasma Concentration (Cmax)

    Cmax.

    Time frame: 6 months

  4. Ph 1a: PK Profile of 225Ac-ABD147 - Area under the plasma concentration versus time curve (AUC)

    AUC.

    Time frame: 6 months

  5. Ph 1a: PK Profile of 225Ac-ABD147 - Volume of Distribution (Vd)

    Vd.

    Time frame: 6 months

  6. Ph 1a: PK Profile of 225Ac-ABD147 - Elimination

    Half-life.

    Time frame: 6 months

  7. Ph 1a: PK Profile of 225Ac-ABD147 - Elimination

    Clearance.

    Time frame: 6 months

  8. Ph 1a: Immunogenicity of 225Ac-ABD147 - Measurement of Anti-drug antibodies

    Anti-drug antibody to ABD147.

    Time frame: 6 months

  9. Ph 1a: Safety of 111In-ABD147 - Number and Grade of Adverse Events

    Incidence of adverse events and serious adverse events graded according to NCI-CTCAE v5.0.

    Time frame: 2 weeks

07

Study locations

12 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Aug 2026, 17 months after the start.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's planned 17 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Dec 16, 2024
StartActual
Mar 10, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Jan 2027
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06736418
Lead sponsor
Abdera Therapeutics Inc.
Responsible party
Sponsor
First posted
Dec 16, 2024
Start date
Mar 10, 2025
Primary completion
Aug 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Apr 24, 2026

Study contacts

Guanying Wang, MD, MS
study director · Abdera Therapeutics Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion